Wall Street brokerages forecast that Sierra Oncology, Inc. (NASDAQ:SRRA – Get Rating) will post earnings per share of ($0.95) for the current quarter, according to Zacks. Zero analysts have made estimates for Sierra Oncology’s earnings. The highest EPS estimate is ($0.88) and the lowest is ($1.02). Sierra Oncology posted earnings per share of ($1.67) in the same quarter last year, which suggests a positive year-over-year growth rate of 43.1%. The company is scheduled to announce its next quarterly earnings results on Monday, January 1st.
On average, analysts expect that Sierra Oncology will report full-year earnings of ($4.79) per share for the current fiscal year, with EPS estimates ranging from ($5.91) to ($3.90). For the next financial year, analysts expect that the firm will report earnings of ($3.60) per share, with EPS estimates ranging from ($4.42) to ($3.10). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Sierra Oncology.
Sierra Oncology (NASDAQ:SRRA – Get Rating) last issued its quarterly earnings data on Thursday, March 10th. The biotechnology company reported ($1.67) earnings per share for the quarter, missing the consensus estimate of ($1.60) by ($0.07).
In related news, insider William D. Turner sold 3,453 shares of the business’s stock in a transaction that occurred on Thursday, March 17th. The shares were sold at an average price of $37.06, for a total transaction of $127,968.18. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, General Counsel Mary Christina Thomson sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, April 4th. The shares were sold at an average price of $35.14, for a total transaction of $70,280.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 5,553 shares of company stock worth $201,957. 67.68% of the stock is currently owned by insiders.
A number of hedge funds have recently bought and sold shares of SRRA. Frazier Life Sciences Management L.P. bought a new stake in Sierra Oncology in the first quarter worth approximately $75,067,000. Deep Track Capital LP acquired a new stake in shares of Sierra Oncology in the fourth quarter worth $13,209,000. Frazier Management LLC lifted its stake in shares of Sierra Oncology by 57.2% in the fourth quarter. Frazier Management LLC now owns 1,264,861 shares of the biotechnology company’s stock worth $27,498,000 after buying an additional 460,194 shares during the last quarter. Goldman Sachs Group Inc. acquired a new stake in shares of Sierra Oncology in the first quarter worth $14,134,000. Finally, BlackRock Inc. lifted its stake in shares of Sierra Oncology by 1,812.7% in the first quarter. BlackRock Inc. now owns 448,430 shares of the biotechnology company’s stock worth $14,372,000 after buying an additional 424,985 shares during the last quarter. 99.30% of the stock is owned by institutional investors.
NASDAQ:SRRA traded up $0.02 during mid-day trading on Friday, hitting $54.75. The stock had a trading volume of 199,288 shares, compared to its average volume of 402,407. The stock has a market capitalization of $1.34 billion, a price-to-earnings ratio of -8.09 and a beta of 0.01. The company has a 50 day simple moving average of $46.06 and a 200-day simple moving average of $32.47. Sierra Oncology has a 52 week low of $14.91 and a 52 week high of $54.97. The company has a current ratio of 21.27, a quick ratio of 21.27 and a debt-to-equity ratio of 0.02.
Sierra Oncology Company Profile (Get Rating)
Sierra Oncology, Inc, a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor.
- Get a free copy of the StockNews.com research report on Sierra Oncology (SRRA)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Will John Deere’s Earnings Help to Calm the Markets?
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Lowe’s Companies Has Not Bottomed
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sierra Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology and related companies with MarketBeat.com's FREE daily email newsletter.